U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H11N3O3S
Molecular Weight 229.256
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LAMIVUDINE

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2

InChI

InChIKey=JTEGQNOMFQHVDC-NKWVEPMBSA-N
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

HIDE SMILES / InChI
Molecular Formula C8H11N3O3S
Molecular Weight 229.256
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:16:11 UTC 2023
Edited
by admin
on Sat Dec 16 05:16:11 UTC 2023
Record UNII
2T8Q726O95
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LAMIVUDINE
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
TEMIXYS COMPONENT LAMIVUDINE
Common Name English
EPIVIR
Brand Name English
LAMIVUDINE [EP MONOGRAPH]
Common Name English
4-AMINO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDIN-2(1H)-ONE [WHO-IP]
Systematic Name English
EMTRICITABINE IMPURITY C [WHO-IP]
Common Name English
KIVEXA COMPONENT LAMIVUDINE
Common Name English
LAMIVUDINUM [WHO-IP LATIN]
Common Name English
GR-109714X
Code English
COMBIVIR COMPONENT LAMIVUDINE
Common Name English
LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT LAMIVUDINE
Brand Name English
TRIZIVIR COMPONENT LAMIVUDINE
Brand Name English
VIROLAM
Common Name English
LAMIVUDINE [WHO-IP]
Common Name English
NSC-760061
Code English
LAMIVUDINE [USP-RS]
Common Name English
3TC
Code English
TELURA COMPONENT OF LAMIVUDINE
Common Name English
LAMIVUDINE COMPONENT OF TRIUMEQ
Brand Name English
LAMIVUDINE COMPONENT OF TRIZIVIR
Brand Name English
LAMIVUDINE COMPONENT OF DUTREBIS
Brand Name English
GR109714X
Code English
LAMIVUDINE COMPONENT OF DELSTRIGO
Brand Name English
LAMIVUDINE COMPONENT OF COMBIVIR
Common Name English
DELSTRIGO COMPONENT LAMIVUDINE
Brand Name English
LAMIVUDINE COMPONENT OF TEMIXYS
Common Name English
LAMIVUDINE [ORANGE BOOK]
Common Name English
Lamivudine [WHO-DD]
Common Name English
LAMIVUDINE TEVA
Brand Name English
lamivudine [INN]
Common Name English
LAMIVUDINE [EP IMPURITY]
Common Name English
ZEFFIX
Brand Name English
LAMIVUDINE [HSDB]
Common Name English
LAMIVUDINE [JAN]
Common Name English
LAMIVUDINE TEVA PHARMA B.V.
Brand Name English
(-)-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE
Systematic Name English
LAMIVUDINE [EMA EPAR]
Common Name English
LAMIVUDINE COMPONENT OF EPZICOM
Common Name English
BCH 189, (-)-
Code English
TRIUMEQ COMPONENT LAMIVUDINE
Brand Name English
LAMIVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA
Brand Name English
LAMIVUDINE [MART.]
Common Name English
EPZICOM COMPONENT LAMIVUDINE
Common Name English
LAMIVUDINE [USAN]
Common Name English
LAMIVUDINE [VANDF]
Common Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-, (2R-CIS)-
Common Name English
LAMIVUDINE [USP MONOGRAPH]
Common Name English
LAMIVUDINE [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175462
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-VATC QJ05AR04
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR05
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-VATC QJ05AR02
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
NCI_THESAURUS C97452
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS LAMIVUDINE TEVA PHARMA B.V. (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-VATC QJ05AR05
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS KIVEXA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-VATC QJ05AR11
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR02
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR11
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/NEV/ZID)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR16
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
NDF-RT N0000175459
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
NDF-RT N0000175656
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
NDF-RT N0000175459
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS ZEFFIX (AUTHORIZED: HEPTATIS B, CHRONIC)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR24
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR12
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR07
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
NDF-RT N0000009947
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS EPIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/NEV/STA)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
LIVERTOX NBK548553
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR01
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR13
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AR04
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS TRIUMEQ (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-VATC QJ05AR01
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS LAMIVUDINE/ZIDOVUDINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
NDF-RT N0000175459
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ATC J05AF05
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-VATC QJ05AR07
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS COMBIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS TRIZIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/ZID)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS LAMIVUDINE TEVA (AUTHORIZED: HEPATITIS B, CHRONIC)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
EMA ASSESSMENT REPORTS DUTREBIS (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
WHO-VATC QJ05AF05
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
Code System Code Type Description
SMS_ID
100000085444
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
INN
6908
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
RXCUI
68244
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY RxNorm
CHEBI
63577
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
CAS
134678-17-4
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
FDA UNII
2T8Q726O95
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
LACTMED
Lamivudine
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
LAMIVUDINE
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY Description: A white or almost white powder.Solubility: Soluble in water; sparingly soluble in methanol R; practically insoluble in acetone R. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Lamivudine should be kept in a well-closed container, protected from light. Additional information: Lamivudine may exhibit polymorphism. Definition: Lamivudine contains not less than 97.0% and not more than 103.0% of C8H11N3O3S, calculated with reference to the dried substance.
MESH
D019259
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
ChEMBL
CHEMBL141
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
NCI_THESAURUS
C1471
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
HSDB
7155
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
USAN
DD-86
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
EPA CompTox
DTXSID7023194
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
WIKIPEDIA
LAMIVUDINE
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
DRUG BANK
DB00709
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
NSC
760061
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
EVMPD
SUB08392MIG
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
MERCK INDEX
m6672
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY Merck Index
DAILYMED
2T8Q726O95
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
PUBCHEM
60825
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
DRUG CENTRAL
1539
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
RS_ITEM_NUM
1356836
Created by admin on Sat Dec 16 05:16:11 UTC 2023 , Edited by admin on Sat Dec 16 05:16:11 UTC 2023
PRIMARY
Related Record Type Details
Structure of LAMIVUDINE METHANOL SOLVATE
SOLVATE->ANHYDROUS
Structure of LAMIVUDINE METHANOL SOLVATE
SALT/SOLVATE -> PARENT
Structure of LAMIVUDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of LAMIVUDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
TARGET ORGANISM->INHIBITOR
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 POLYMERASE
TARGET -> INHIBITOR
HEPATITIS B VIRUS
TARGET ORGANISM->INHIBITOR
Related Record Type Details
Structure of LAMIVUDINE TRIPHOSPHATE
METABOLITE ACTIVE -> PARENT
Structure of LAMIVUDINE SULFOXIDE, (S)-
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of TROXACITABINE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 5-(4-AMINO-2-OXOPYRIMIDIN-1(2H)-YL)-1,3-OXATHIOLANE-2-CARBOXYLIC ACID, CIS-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYTOSINE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of LAMIVUDINE SULFOXIDE, (R)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of LAMIVUDINE SULFOXIDE, (S)-
IMPURITY -> PARENT
Structure of LAMIVUDINE SULFOXIDE, (R)-
IMPURITY -> PARENT
Structure of URACIL
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of LAMIVUDINE, (±)-TRANS-
IMPURITY -> PARENT
Structure of 1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDINE-2,4(1H,3H)-DIONE, (2R,5S)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of URACIL
IMPURITY -> PARENT
Use the chromatogram supplied with lamivudine for system suitability RS and the chromatogram obtained with solutions (4) and (3) to identify the peaks due to impurity F. The impurity peaks are eluted at the following relative retention times with reference to lamivudine (retention time about 11 to 12 minutes): impurity F (uracil) about 0.36.
Structure of EMTRICITABINE
PARENT -> IMPURITY
Structure of 5-(4-AMINO-2-OXOPYRIMIDIN-1(2H)-YL)-1,3-OXATHIOLANE-2-CARBOXYLIC ACID, CIS-
IMPURITY -> PARENT
Structure of Salicylic acid
IMPURITY -> PARENT
Use the chromatogram supplied with lamivudine for system suitability RS and the chromatogram obtained with solutions (4) and (3) to identify the peaks due to impurity C. The impurity peaks are eluted at the following relative retention times with reference to lamivudine (retention time about 11 to 12 minutes): impurity C (salicylic acid) about 2.6. In the chromatogram obtained with solution (1): - the area of any peak corresponding to impurity C is not greater than that of the principal peak in the chromatogram obtained with solution (3) (0.1%).
Structure of 1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDINE-2,4(1H,3H)-DIONE, (2R,5S)-
IMPURITY -> PARENT
Structure of Salicylic acid
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYTOSINE
IMPURITY -> PARENT
Structure of CYTOSINE
IMPURITY -> PARENT
Use the chromatogram supplied with lamivudine for system suitability RS and the chromatogram obtained with solutions (4) and (3) to identify the peaks due to impurity F. The impurity peaks are eluted at the following relative retention times with reference to lamivudine (retention time about 11 to 12 minutes): impurity E (cytosine) about 0.31. In the chromatogram obtained with solution (1):- the area of any individual peak corresponding to impurity E, when multiplied by a correction factor of 0.6, is not greater than the area of the peak in the chromatogram obtained with solution (2) (0.1%).
Structure of LAMIVUDINE, (+)-CIS-
IMPURITY -> PARENT
Structure of TROXACITABINE
IMPURITY -> PARENT
Structure of LAMIVUDINE, (±)-TRANS-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of URACIL
IMPURITY -> PARENT
Structure of LAMIVUDINE, (+)-CIS-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Salicylic acid
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LAMIVUDINE SULFOXIDE, (S)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
Structure of LAMIVUDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Intercellular
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966